Oncopeptides AB (publ) (ONPPF)
USD 0.27
(0.0%)
USD 0.27
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -231.62 Million SEK | 27.54% |
| 2022 | -319.63 Million SEK | 77.26% |
| 2021 | -1.4 Billion SEK | 10.85% |
| 2020 | -1.51 Billion SEK | -114.54% |
| 2019 | -747.34 Million SEK | -75.4% |
| 2018 | -419.79 Million SEK | -69.35% |
| 2017 | -247.34 Million SEK | -116.21% |
| 2016 | -114.45 Million SEK | -114.54% |
| 2015 | -53.34 Million SEK | -61.19% |
| 2014 | -33.1 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -73.25 Million SEK | -11.56% |
| 2024 Q1 | -65.66 Million SEK | 6.46% |
| 2023 Q2 | -62.43 Million SEK | 14.17% |
| 2023 Q3 | -37.29 Million SEK | 40.26% |
| 2023 Q1 | -72.74 Million SEK | 17.34% |
| 2023 Q4 | -70.19 Million SEK | -88.21% |
| 2023 FY | - SEK | 27.54% |
| 2022 Q1 | -98.86 Million SEK | 74.61% |
| 2022 FY | - SEK | 77.26% |
| 2022 Q2 | -61.08 Million SEK | 38.21% |
| 2022 Q4 | -87.99 Million SEK | 0.97% |
| 2022 Q3 | -88.85 Million SEK | -45.45% |
| 2021 Q4 | -389.34 Million SEK | -14.88% |
| 2021 FY | - SEK | 10.85% |
| 2021 Q1 | -347.33 Million SEK | 32.06% |
| 2021 Q2 | -344.83 Million SEK | 0.72% |
| 2021 Q3 | -338.91 Million SEK | 1.72% |
| 2020 Q4 | -511.25 Million SEK | -33.31% |
| 2020 Q3 | -383.49 Million SEK | 3.97% |
| 2020 Q1 | -296.87 Million SEK | -21.55% |
| 2020 FY | - SEK | -114.54% |
| 2020 Q2 | -399.33 Million SEK | -34.51% |
| 2019 Q3 | -189.59 Million SEK | -10.4% |
| 2019 FY | - SEK | -75.4% |
| 2019 Q4 | -244.24 Million SEK | -28.82% |
| 2019 Q2 | -171.73 Million SEK | -40.85% |
| 2019 Q1 | -121.93 Million SEK | -9.64% |
| 2018 Q1 | -68.45 Million SEK | -2.62% |
| 2018 FY | - SEK | -69.35% |
| 2018 Q4 | -111.21 Million SEK | -7.99% |
| 2018 Q3 | -102.98 Million SEK | 28.02% |
| 2018 Q2 | -143.07 Million SEK | -109.02% |
| 2017 Q4 | -66.7 Million SEK | -29.34% |
| 2017 Q1 | -62.08 Million SEK | -21.61% |
| 2017 Q2 | -67.26 Million SEK | -8.34% |
| 2017 Q3 | -51.57 Million SEK | 23.32% |
| 2017 FY | - SEK | -116.21% |
| 2016 Q1 | -15.24 Million SEK | 0.0% |
| 2016 Q2 | -23.48 Million SEK | -54.07% |
| 2016 Q4 | -51.05 Million SEK | -106.96% |
| 2016 FY | - SEK | -114.54% |
| 2016 Q3 | -24.66 Million SEK | -5.04% |
| 2015 FY | - SEK | -61.19% |
| 2014 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.06 Million USD | -7461.893% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -6430.085% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -10038.898% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -1233.46% |
| GB Sciences, Inc. | -1.41 Million USD | -16212.73% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 61239.15% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -1893938.76% |
| Skye Bioscience, Inc. | -13.54 Million USD | -1609.697% |
| Zenith Capital Corp. | -8.6 Million USD | -2591.401% |
| Agentix Corp. | -1.37 Million USD | -16785.073% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -5863.0% |
| Biomind Labs Inc. | -1.03 Million USD | -22288.693% |
| ContraFect Corporation | -64.99 Million USD | -256.347% |
| CSL Limited | 4.78 Billion USD | 104.837% |
| CytoDyn Inc. | -18.02 Million USD | -1184.719% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 3444805.532% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -36525.522% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | -318.551% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -62974.28% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -14979.076% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -24620.876% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 346.306% |
| SQZ Biotechnologies Company | -64.14 Million USD | -261.114% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -15472.148% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | -226.063% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -8658.803% |
| Mesoblast Limited | -62.38 Million USD | -271.25% |
| Marizyme, Inc. | -34.28 Million USD | -575.648% |
| Genus plc | 73.7 Million USD | 414.277% |
| Pharming Group N.V. | 9.87 Million USD | 2445.064% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -2540.47% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -16423.09% |
| IMV Inc. | -35.52 Million USD | -552.027% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -9867.295% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -44610.701% |
| ONE Bio Corp. | 13.61 Million USD | 1801.471% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -380.275% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 6584.378% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -7908.157% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -3134.368% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -926388.0% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -1359.52% |
| Alpha Cognition Inc. | -9.7 Million USD | -2286.478% |
| Enzolytics Inc. | -2.12 Million USD | -10815.119% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | -7.221% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 19132.21% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 2716.074% |
| Genscript Biotech Corporation | -248.71 Million USD | 6.874% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -3806.655% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -96752.185% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -9367.635% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -131485.197% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -11957.925% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -3403.311% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -5017.367% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -6082.491% |
| Helix BioMedix, Inc. | -1.04 Million USD | -22036.992% |
| EV Biologics, Inc. | -1.26 Million USD | -18179.232% |
| Q BioMed Inc. | -617.62 Thousand USD | -37401.862% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -13135.55% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -484.36% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | -2966.361% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -9157.615% |
| HST Global, Inc. | -5303.00 USD | -4367654.101% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -11160.185% |
| Halberd Corporation | -74.27 Thousand USD | -311727.031% |
| Resverlogix Corp. | -11.74 Million USD | -1872.594% |
| Cell Source, Inc. | -4.27 Million USD | -5321.196% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -15352.737% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.11 Million USD | -3689.228% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -1329456.283% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | -22283.327% |
| Kadimastem Ltd | -2.62 Million USD | -8725.776% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -60914.172% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -127805.77% |
| LadRx Corporation | 412.28 Thousand USD | 56280.342% |
| Regen BioPharma, Inc. | 1.46 Million USD | 15900.065% |
| Affymax, Inc. | -14.29 Million USD | -1520.301% |
| Itoco Inc. | -1.86 Million USD | -12292.864% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -20654.659% |
| Mobile Lads Corp. | -2.24 Million USD | -10234.92% |
| International Stem Cell Corporation | 202 Thousand USD | 114764.356% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | -5963.17% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -292984.817% |
| Qrons Inc. | -40.08 Thousand USD | -577784.783% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -47590.445% |
| SYBLEU INC | -141.57 Thousand USD | -163508.366% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 44014.962% |
| Rebus Holdings, Inc. | -951 Thousand USD | -24255.626% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -21709.776% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -439911.398% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -9308.14% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -545.744% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -514615.556% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -8359.533% |
| Neutra Corp. | -181.24 Thousand USD | -127693.563% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -1048.976% |
| PureTech Health plc | -11.62 Million USD | -1892.105% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -1049.054% |
| IXICO plc | -707 Thousand USD | -32661.245% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -2913.949% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -379.092% |
| CSL Limited | 4.73 Billion USD | 104.894% |
| Cellectis S.A. | -92.63 Million USD | -150.035% |